Phase I Study of Intrathecal Topotecan

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma, Meningeal Neoplasms

In brief

The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).

Key facts

Study ID

NCT00001333

Run by

National Cancer Institute (NCI)

People needed

30

Starts

1993-02-01

Expected to finish

2000-12-01

Last updated by the study team

2008-03-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• National Cancer Institute (NCI) — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.